# Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

> **NCT06364319** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 118 (estimated)

## Conditions studied

- cGVHD

## Interventions

- **DRUG:** anti-CD25 rhMAb
- **DRUG:** Prednisone
- **DRUG:** Ruxolitinib
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT06364319
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364319, "Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06364319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*